Our results demonstrate a notable proportion of patients qualifying for a potential inclusion in studies examining the efficacy of GLP-1-RA agonists and SGLT-2 inhibitors in secondary prevention of cardiovascular events for ischemic stroke patients, indicating feasibility of future clinical trials. Here, SLC5A2 is linked to ischemic stroke.